Leadership ( D1 f6 U- L2 W. u) YThe charter members of the Alliance for Regenerative Medicine (Alliance) approved bylaws and elected officers and an executive committee at its first official meeting on September 22, 2009. - j. k5 {* z6 U% N; ^Officers5 v! M2 v) V; R& y+ `7 M
Chair – John Walker: Chief Executive Officer, iPierian ! |9 |3 f ]" z" B' J! IVice Chair – Anthony Atala, MD: W.H. Boyce Professor, Director of the Institute for Regenerative Med. and chair of the Dept. of Urology at Wake Forest University 9 i1 `% t' u, [0 SSecretary – Leona Brenner-Gati, MD: Vice President of Science and Technology, Johnson & Johnson’s Corporate Office of Science and Technology 9 k% Q' ]: n) O- c U$ STreasurer – Dean Tozer: Senior Vice President, Advanced BioHealing 7 Z1 o3 [) i6 j" LFrom the Officers...9 m& ~% u, Y. a* c* d
“I am delighted and honored to serve as the first chairman of the Alliance for Regenerative Medicine. The regenerative medicine community needs a strong and focused political voice and I am confident that this group of leading companies, research institutions, and non-profits that has come together will do just that,” stated John Walker, CEO and president of iPierian and the newly-elected Chair of the Alliance. “With the accelerating pace of development in regenerative medicine and new therapeutic advancements being introduced into the clinic at an ever increasing rate, it has never been more important that the companies and researchers involved in this field work together,” added Dr. Anthony Atala, vice chair of the Alliance and the W.H. Boyce Professor, Director of the Institute for Regenerative Medicine and chair of the Department of Urology at Wake Forest University. ' q0 l' _/ {3 N3 y$ n2 QCommittees9 l: k9 k ?' y/ q* l7 Z
Executive Committee& v& b: e, O% [+ a8 b8 a# \" n
The Alliance’s first executive committee includes: i# |+ Q( F) C' k
• Dr. Anthony Atala: Director, Wake Forest Institute for Regenerative Medicine . [4 F8 i. H- M8 R) e; o4 ~
• Dr. Leona Brenner-Gati: Vice President, Corp. Office of Science and Tech., J&J * k1 D6 b' ]9 Q' h9 p( V3 J+ D• Dr. Ray Cypess: President and CEO, ATCC 4 v! W/ U7 U( i& `• Doug Doerfler: President and CEO, MaxCyte ' ~: H, y8 G3 d# o
• Ed Field: President & COO, Aldagen 6 d' C9 m3 l2 U1 O+ i6 k9 R8 U( U% u• Gary Kurtzman: Vice President, Life Sciences, Safeguard Scientifics 1 Z; t3 P" d& y/ K7 U8 a
• Alan Lewis: President, Juvenile Diabetes Research Foundation 5 h L/ d3 J- ?0 R7 G
• Martin McGlynn: President and CEO, Stem Cells Inc. * t$ X" \+ U: I" I$ v) d5 }
• John McNeish: Executive Director, Regenerative Medicine, Pfizer 1 c+ N. E N8 U! h+ h$ c: L% r• Dr. George Muschler: Vice Chair, Orthopedic and Rheumatologic Inst., Cleveland Clinic / h# P* g. e/ o! _7 }
• Dr. Steven Nichtberger: President and CEO, Tengion % W3 s( s6 u# @, P! s• Dr. Tom Okarma: President and CEO, Geron , j8 h7 \. u4 W
• Dr. Beth Seidenberg: Partner, Kleiner, Perkins, Caufield, and Byers . S; J, T( o3 [! \/ x9 z) Q" p+ j• Bernard Siegel: Executive Director, Genetics Policy Institute 0 {7 J5 j) E% X* B+ S: F2 ^
• Dean Tozer: Senior Vice President, Advanced BioHealing % Z8 o+ {2 ^, T! j0 D1 G4 j
• John Walker: President and CEO, iPierian 8 T5 F7 k; Y: R4 w$ f( o• Scott Wolchko: Chief Financial Officer, Fate Therapeutics # Q3 e7 x& _" u; u; jCommunication and Education Committee; n _3 l f: ?0 }0 s
CHAIR: Dean Tozer, Senior Vice President, Advanced BioHealing ( `# o% I% b% `+ P9 M+ \
The Communication and Education Committee has primary responsibility for overseeing the Alliance’s communications activities, including interaction with the media. With respect to education, it guides development of an education agenda to support broader understanding of the benefits and challenges facing individuals and organizations involved in regenerative medicine. The Committee also manages engagement with the patient advocacy community in order to broaden its understanding and support for regenerative medicine.: r8 P- s3 G( A( C5 Z6 ^
Membership Committee! r, u% ?( ]1 v8 F- W# m( a
CHAIR: John McNeish, Executive Director, Regenerative Medicine, Pfizer / S. \+ L; r: n, c
The Membership Committee manages the membership recruitment activities of the Alliance. It assists staff with recruitment of new members and encourages participation of all Alliance members in recruitment activities. It also directs the fulfillment of current member programs and develops new programs and activities to benefit the membership.: s' {: q4 U( [- t2 a) L
Government Relations & Policy Committee 5 j! W- o0 k3 |4 k1 |+ K! ZCHAIR: Thomas Okarma, President and CEO, Geron ( u8 p! u/ ~" ~8 C+ A3 p/ O5 |The Committee assists Alliance staff in understanding the impact of existing law and regulations and proposed legislation on the regenerative medicine community. The Committee guides the development of an advocacy agenda and executes the lobbying strategy for the Alliance on Capitol Hill. It focuses on both authorization programs and appropriations for regenerative medicine funding. The Committee also advocates for programs to fund regenerative medicine research at NIH, SBA, and elsewhere. The members of the Committee are responsible for formal interaction with Congress, congressional staff, and federal agencies including testifying, attending meetings, and other activities as appropriate. ; a( k- W/ }( O8 H: Q
Regulatory and Reimbursement Committee 8 F6 Y, P) W4 I: L9 e; ]2 B8 N) HCHAIR: Ed Field, President and COO, Aldagen q+ E' Y% ?7 e) r7 v
The Regulatory Committee oversees development and implementation of the regulatory agenda for the Alliance. This includes prioritization of regulatory objectives with key agencies such as the Food and Drug Administration, the Centers for Medicare and Medicaid Services, the Patent and Trademark Office. The Regulatory Committee is responsible for formal interaction with the regulatory agencies at public hearings, roundtables, PDUFA negotiations, and other instances where company representatives are invited to discuss regulatory matters on behalf of the broader regenerative medicine community.' h+ f" {0 {/ m% D
Science and Technology Committee4 Q' P1 @4 {/ G G9 i& T8 Y) [
CHAIR: Alan Trounson, President, CIRM; Doug Doerfler, President and CEO, MaxCyte ! n! Z+ G' r% A1 H' ^The S&T Committee serves as a forum for Alliance members to exchange ideas, information, and data on different science and technology issues within the regenerative medicine field. One of the principal responsibilities of the Committee is to consider issues relating to process and research standards in the context of regulatory science that could be adopted by the industry after consultation with other interested and qualified organizations and the appropriate federal agencies.作者: 剑啸寒 时间: 2015-6-8 16:17